岸田 健 先生のプロフィール

【論文】
Kishida T, YaoM, Chen F, Orcutt ML, Lerman MI, Zbar B: A novel donor splice site mutation associated with two mRNAs in von Hippel-Lindau disease. Hum Mol Genet 3: 1991-1992, 1994.
Kishida T, Chen F, Lerman MI Zbar B: Detection of germline mutations in the von Hippel-Lindau disease gene by the polymerase chain reaction with modified primers. J Med Genet 32: 938-941, 1995.
Kishida T, StackhauseT, ChenF, LermanMI ZbarB: Cellular Proteins That Bind the von Hippel-Lindau Disease Gene Product: Mapping of Binding Domains and the Effect of Missense Mutations. Cancer Res 55:4544-4548, 1995.
Foster RE, Abdulrahman M, Morris MR, Prigmore E, Gribble S, Ng B, Gentle D, Ready S, Weston PM, Wiesener MS, Kishida T, Yao M, Davison V, Barbero JL, Chu C, Carter NP, Latif F, Maher ER. Characterization of a 3;6 translocation associated with renal cell carcinoma. Genes Chromosomes Cancer 46(4): 311-7. 2006
Murakami T, Sano F, Huang Y, Komiya A, Baba M, Osada Y, Nagashima Y, Kondo K, Nakaigawa N, Miura T, Kubota Y, Yao M, Kishida T. Identification and characterization of Birt-Hogg-Dube associated renal carcinoma.J Pathol. 2007 Feb 26;211(5):524-531
Significance of thcg assay in the management of testicular cancer--the possibility of a standard assay in testicular cancer as an alternative to FbetahCG assay. Nippon Hinyokika Gakkai Zasshi. 2007 Jan;98(1):23-9. Japanese.
Kishida T. Renal cryoablation: still experimental? Int J Urol., 13(7): 885, 2006.
Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, Kubota Y, Nagashima Y, Yao M. Expression of Aquaporin 1 in Primary Renal Tumors: A Prognostic Indicator for Clear-Cell Renal Cell Carcinoma. Eur Urol. 2008 Oct 14.
Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Sano F, Baba M, Kondo K, Nakaigawa N, Kishida T, Nagashima Y, Yamada-Okabe H, Kubota Y. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int J Cancer. 2008 Sep 1;123(5):1126-32.
Takizawa A, Kishida T, Miura T, Hattori Y, Noguchi K, Kubota Y. Clinical significance of low level human chorionic gonadotropin in the management of testicular germ cell tumor. J Urol. 2008 Mar;179(3):930-4; discussion 934-5.
Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Teh BT, Latif F, Maher ER. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer. 2008 Jan 29;98(2):496-501.
Sakuma Y, Matsukuma S, Yoshihara M, Sakurai S, Nishii M, Kishida T, Kubota Y, Nagashima Y, Inayama Y, Sasaki T, Nakamura Y, Miura T, Kameda Y, Tsuchiya E, Miyagi Y. Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan. Cancer Lett. 2008 Jan 18;259(1):119-26
Kishida T, Yao M, Uemura H, Ohlmann C, Tomita Y, Bukowski RM, Naito S. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy. Int J Urol. 2010 Mar;17(3):198-205.
Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010 Apr 8;29(14):2104-17
Kakizoe M, Takizawa A, Hattori Y, Teranishi J, Kondou K, Kishida T, Saitou K, Noguchi K, Kubota Y, Murakami A, Sasaki T. Case of lymphangiomyomatosis of the kidney and retroperitoneum. Hinyokika Kiyo. 2009 May;55(5):249-52
McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, Clarke NW, Brown MD, Kishida T, Yao M, Latif F, Maher ER. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009 Jun 3;8:31
Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, Miura T, Makiyama K, Yao M, Kubota Y, Inoue T. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med. 2010 Dec;35(12):918-23.
Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2010 Dec 6.
Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010 Dec 3;10:667.
Kishida T, Yao M, Uemura H, Ohlmann C, Tomita Y, Bukowski RM, Naito S. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy. Int J Urol. 2010 Mar;17(3):198-205.
Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010 Apr 8;29(14):2104-17. Epub 2010 Feb 15
Shuib S, Wei W, Sur H, Morris MR, McMullan D, Rattenberry E, Meyer E, Maxwell PH, Kishida T, Yao M, Latif F, Maher ER. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma. Genes Chromosomes Cancer. 2011 Jul;50(7):479-88. doi: 10.1002/gcc.20865. Epub 2011 Mar 31.
Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2011 Mar 24;30(12):1390-401. Epub 2010 Dec 6.
Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K, Eto M, Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y, Abe T, Fujioka T, Ito K, Naito S. Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan.; Members of the Japanese Society of Renal Cancer. BMC Cancer. 13: 447, 2013
Alholle A, Brini AT, Gharanei S, Vaiyapuri S, Arrigoni E, Dallol A, Gentle D, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F. Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma. Epigenetics. 8(11):1198-20, 2013
Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics. 8(9):893-8, 2013
Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics. 2013 Sep;8(9):893-8. doi: 10.4161/epi.25617. Epub 2013 Jul 18.
Ito H, Shioi K, Murakami T, Takizawa A, Sano F, Kawahara T, Mizuno N, Makiyama K, Nakaigawa N, Kishida T, Miura T, Kubota Y, Yao M. C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer. 2012 Aug 2;12:337. doi: 10.1186/1471-2407-12-337.
Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Inoue T, Kubota Y, Nakaigawa N. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer. 2012 May 2;12:162. doi: 10.1186/1471-2407-12-162.
Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K, Eto M, Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y, Abe T, Fujioka T, Ito K, Naito S. Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan.; Members of the Japanese Society of Renal Cancer. BMC Cancer. 13:447, 2013
Alholle A, Brini AT, Gharanei S, Vaiyapuri S, Arrigoni E, Dallol A, Gentle D, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F. nctional epigenetic approach identifies frequently methylated genes in Ewing sarcoma. pigenetics. 8(11):1198-20, 2013
Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics. 8(9):893-8, 2013
河野 充, 岸田 健, 藤川 敦, 村岡 研太郎, 石田 寛明, 三浦 猛, 田中 克幸: 長期膀胱瘻の頸髄損傷患者に発症し急速に進行した膀胱癌の1例. 日本泌尿器科学会雑誌104巻4号:612-615,2013
岸田　健:　Sorafenib を投与し、ＰＲの後に一時増大するも投与継続により再度縮小が得られた腎細胞癌症例.　RCC Today vol.10: 9-10, 2013

【総説】
矢尾正祐、中井川昇、近藤慶一、岸田健. 腎細胞癌の分子標的　ＶＨＬを中心に. Urology View 特集：これからはじまる進行腎癌に対する分子標的薬治療vol.6(4)23-29 2008 Aug
中井川昇、岸田健、矢尾正祐、窪田吉信. 非淡明細胞癌の臨床はどう変化する. Urology View 特集：これからはじまる進行腎癌に対する分子標的薬治療vol.6(4) 78-84 2008 Aug
岸田 健 , 矢尾 正祐. 腎癌--分子標的治療薬時代のサイトカイン療法の役割 (特集 泌尿器科の癌薬物療法--ここが聞きたい) . 臨床泌尿器科 63(5), 301-309, 2009-04
岸田　健、滝沢明利、服部裕介、三浦猛、窪田吉信. 精巣腫瘍治療における腫瘍マーカー測定上の問題点(精巣腫瘍の診断と治療Update). Urology View vol.7(3) 47-51　2010
岸田健*1, 滝沢明利*2.精巣腫瘍におけるアジュバント療法. 泌尿器外科, 23(12) : 1725-1730, 2010.4
*1神奈川県立がんセンター泌尿器科, *2横浜みなと赤十字病院泌尿器科
岸田健. 腎臓癌の原因遺伝子の解明と分子標的治療薬の進歩. Vita vol27(4) 59-67,2010.10
岸田健(神奈川県立がんセンター 泌尿器科). 非淡明細胞癌(肉腫様変化を含む)に対する治療戦略　乳頭状腎細胞癌、嫌色素性腎細胞癌に対する治療戦略. 泌尿器外科(0914-6180)24巻特増 Page779-780(2011.05)
矢尾正祐(横浜市立大学 大学院医学研究科泌尿器分子遺伝学), 中井川昇, 長嶋洋治, 岸田健. 疫学、診断(画像、病理、分子発生学)、予後因子　腎癌　分子発生学. 泌尿器外科(0914-6180)24巻特増 Page715-716(2011.05)
岸田健、原田知彦. 切り取って使える保存版泌尿器科薬剤ノート(2)泌尿器がんの薬 精巣腫瘍に用いる薬(解説/特集). 泌尿器ケア18巻10号 :1078-1082,2013
岸田健. なぜ必要?どこに注目?泌尿器科病棟で必要な検査値を理解しよう！腫瘍マーカー(精巣腫瘍). 泌尿器ケア18巻7号:703-708,2013
岸田健、滝沢昭利、服部裕介、三浦猛、窪田吉信. 精巣腫瘍治療における腫瘍マーカー測定上の問題点. Urology View vol.7 No.3: 47-51, 2013
岸田健. Non clear cell RCCに対する分子標的治療；発癌機構から導かれる個別化医療. 臨床泌尿器科　特集　進行性腎癌に対する分子標的治療薬・薬剤選択ガイド　第66巻　第1号:　59-67　2013
岸田健. 精巣腫瘍は治療の貫徹が治癒へのポイント　精巣腫瘍の基礎知識　腎・膀胱・精巣腫瘍特集. がんサポート　vol 130. 1 :40-43 2014
ＥＢＭ　泌尿器疾患の治療　ＩＶ；精巣腫瘍 ６ 腫瘍マーカーが正常化しない場合の救済化外科療法の意義は？ ｐ262-268 2015